Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants - Report - MDSpire
Advertisement
Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants
Trends in Hematopoietic Stem Cell Transplantation in Europe: 2013 Survey Insights
Overview
The 2013 EBMT survey reported a total of 34,809 first hematopoietic stem cell transplants (HSCT) in Europe and affiliated countries, with a notable increase in allogeneic HSCT using haploidentical donors and a decline in cord blood transplants. The total HSCT procedures performed reached 39,209, reflecting a 3.4% increase from 2012.
Background
Hematopoietic stem cell transplantation (HSCT) is a critical treatment for various hematopoietic, immune, and metabolic disorders. The European Society of Blood and Marrow Transplantation (EBMT) conducts annual surveys to monitor HSCT trends, donor types, and stem cell sources across Europe and affiliated countries. These surveys provide valuable data on transplant rates, donor utilization, and emerging cellular therapies, supporting clinical decision-making and policy development.
Data Highlights
Parameter
Number
Percentage
First HSCT Patients
34,809
100%
Allogeneic HSCT
14,950
43%
Autologous HSCT
19,859
57%
Total HSCT Procedures
39,209
100%
Allogeneic Procedures
16,211
41%
Autologous Procedures
22,998
59%
Retransplants
2,710
-
Multiple Transplants
1,690
-
Key Findings
In 2013, 658 transplant teams from 48 countries reported data, achieving a 96% response rate.
There was a 3.4% overall increase in HSCT patients compared to 2012, driven mainly by a 5.5% rise in allogeneic HSCT.
Haploidentical donors (mismatched family donors) saw increased utilization for allogeneic HSCT, reflecting a shift from traditional donor sources.
Cord blood transplants decreased in frequency during 2013.
Most centers (62%) performed both allogeneic and autologous transplants, with 19% treating both adult and pediatric patients.
Additional cellular therapies and detailed transplant data were collected, supporting comprehensive monitoring of HSCT practices.
Clinical Implications
The increased use of haploidentical donors expands donor availability, potentially improving transplant access for patients lacking matched donors. The decline in cord blood transplants may reflect evolving preferences based on outcomes or donor availability. Clinicians should consider these trends when selecting donor sources and planning transplant strategies.
Conclusion
The 2013 EBMT survey highlights evolving HSCT practices in Europe, with growing reliance on haploidentical donors and reduced cord blood use, alongside a steady increase in transplant activity. These data inform clinical and policy decisions to optimize transplant outcomes.
References
European Society of Blood and Marrow Transplantation (EBMT) 2013 Survey Report -- Trends in HSCT
by J R Passweg, H Baldomero, P Bader, C Bonini, S Cesaro, P Dreger, R F Duarte, C Dufour, J H F Falkenburg, D Farge-Bancel, A Gennery, N Kröger, F Lanza, A Nagler, A Sureda, M Mohty
Diagnosing lymphoma and sarcoma can be extraordinarily complex, with more than 70 recognized subtypes of lymphoma and more than 100 distinct types of sarcoma. Many subtypes share similar features yet behave in dramatically different ways in standard testing, leaving oncologists with diagnostic quandaries and delays to treatment.
